Zobrazeno 1 - 9 of 9 pro vyhledávání: '"Georgiy M. Manikhas"'
1
ATL
Autor: Khristina B Kotiv, Alexey M. Belyaev, Georgiy M Manikhas, Anna Sidoruk, Evgeny N. Imyanitov, Anna P. Sokolenko, Galina I Mikhailiuk, Alla S Lisyanskaya, Laslo D Roman, Ekatherina A Nekrasova, Nikolay Mikaya, Tatyana Gorodnova, Alexandr O. Ivantsov, Nikolay Bondarev, Olga N Mikheyeva, K. D. Guseynov, Igor Berlev, Nataliya S Matveyeva
Publikováno v: International Journal of Gynecologic Cancer. 28:1498-1506
ObjectivesCisplatin and mitomycin C exert high activity towards BRCA1-deficient cells. This study aimed to evaluate the efficacy of a combination of these drugs in hereditary BRCA1-associated ovarian cancer (OC).MethodsTwelve OC patients, who could n
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0e4337f604eb0b635d573c7804e8a0a1
https://doi.org/10.1097/igc.0000000000001352
Zobrazit plný text záznamu
2
Aromatase inhibitors of the third generation in endocrine therapy of breast cancer and endometrial cancer: the successes and failures of the combination therapy
Autor: Ruslan Glushakov, Georgiy M Manikhas, Alla S Lisyanskaya, Ekaterina P Fadeeva, Natalia I Tapilskaya
Publikováno v: Reviews on Clinical Pharmacology and Drug Therapy. 14:47-57
This review provides the current evidence of clinical studies on the effectiveness of endocrine therapy for breast cancer and endometrial cancer, including endometrial stromal sarcoma, by aromatase inhibitor (AI) III generation. The review presents d
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3c05ce499aee52319f4087ad863647fd
https://doi.org/10.17816/rcf14247-57
Zobrazit plný text záznamu
3
Efficacy of Neoadjuvant Therapy With Cisplatin Plus Mitomycin C in BRCA1-Mutated Ovarian Cancer
Autor: Tatyana V, Gorodnova, Khristina B, Kotiv, Alexandr O, Ivantsov, Olga N, Mikheyeva, Galina I, Mikhailiuk, Alla S, Lisyanskaya, Nikolay A, Mikaya, Konstantin D, Guseynov, Nikolay E, Bondarev, Nataliya S, Matveyeva, Ekatherina A, Nekrasova, Anna A, Sidoruk, Laslo D, Roman, Georgiy M, Manikhas, Alexey M, Belyaev, Anna P, Sokolenko, Igor V, Berlev, Evgeny N, Imyanitov
Publikováno v: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 28(8)
Cisplatin and mitomycin C exert high activity towards BRCA1-deficient cells. This study aimed to evaluate the efficacy of a combination of these drugs in hereditary BRCA1-associated ovarian cancer (OC).Twelve OC patients, who could not be treated by
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::e0b125a51c93262fd97649837f0556c6
https://pubmed.ncbi.nlm.nih.gov/30247247
Zobrazit plný text záznamu
4
Phase II Trial of Nab-Paclitaxel Compared With Docetaxel as First-Line Chemotherapy in Patients With Metastatic Breast Cancer: Final Analysis of Overall Survival
Autor: P. Bhar, D. Krasnojon, Georgiy M. Manikhas, John R. McGuire, William J. Gradishar, A. Makhson, Jose Iglesias, S. Cheporov, Alicia Clawson
Publikováno v: Clinical Breast Cancer. 12:313-321
Background A randomized phase II study in first-line MBC demonstrated superior efficacy and safety of weekly nab -paclitaxel compared with docetaxel. Final survival analyses and updated safety results are reported. Patients and Methods Three hundred
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a8f4fa70c51c0e23b69cc76ae809865
https://doi.org/10.1016/j.clbc.2012.05.001
Zobrazit plný text záznamu
6
A Dose Finding Study of Weekly and Every-3-Week nab-Paclitaxel Followed by Carboplatin as First-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer
Autor: Georgiy M. Manikhas, A. Makhson, Daniil L. Stroyakovsky, Petr K. Yablonsky, P. Bhar, Sergei V. Orlov, S. Cheporov, Jose Iglesias, Mark A. Socinski
Publikováno v: Journal of Thoracic Oncology. 5:852-861
Introduction This nonrandomized study aimed to identify the optimal dose of every-3-week (q3w) and weekly nab -paclitaxel plus q3w carboplatin as first-line therapy in patients with advanced non-small cell lung cancer (NSCLC) for a phase 3 trial. Met
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a320c1b53f5385f29badb1b76f9309c
https://doi.org/10.1097/jto.0b013e3181d5e39e
Zobrazit plný text záznamu
7
Significantly Longer Progression-Free Survival With nab-Paclitaxel Compared With Docetaxel As First-Line Therapy for Metastatic Breast Cancer
Autor: P. Bhar, Georgiy M. Manikhas, William J. Gradishar, Alicia Clawson, D. Krasnojon, S. Cheporov, A. Makhson
Publikováno v: Journal of Clinical Oncology. 27:3611-3619
Purpose In patients with metastatic breast cancer (MBC), nab-paclitaxel produced significantly higher antitumor activity compared with patients who received solvent-based paclitaxel. This phase II study examined the antitumor activity and safety of w
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc47da1fdba36b1c7ec2f979def71480
https://doi.org/10.1200/jco.2008.18.5397
Zobrazit plný text záznamu
9
Randomized comparison of weekly or every-3-week (q3w) nab-paclitaxel compared to q3w docetaxel as first-line therapy in patients (pts) with metastatic breast cancer (MBC)
Autor: M. J. Hawkins, D. Krasnojon, Georgiy M. Manikhas, A. Makhson, S. Cheporov, Alicia Clawson, William J. Gradishar
Publikováno v: Journal of Clinical Oncology. 25:1032-1032
1032 Background: 130-nM albumin-bound (nab™) paclitaxel combines paclitaxel with albumin without solvents or altering either component. A cross analysis of 2 clinical trials comparing solvent-based (SB) paclitaxel 175 mg/m2 q3w to nab- paclitaxel (
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1f42dc2f09e25fe4675289298d5023c3
https://doi.org/10.1200/jco.2007.25.18_suppl.1032
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje